No abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34884/1/62_ftp.pd
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina,...
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic eff...
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in do...
Thomas Müller Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, 13088, Ge...
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms inc...
Three decades after its introduction, levodopa remains the gold standard for the treatment of Parkin...
Introduction: The clinical diagnosis of Parkinson’s disease (PD) is based on the identification of b...
Parkinson’s disease (PD) is a neurodegenerative disease affecting approximately 25000 people in Swed...
Motor complications in response to levodopa therapy are major problems in the treatment of Parkinson...
Parkinson\u27s disease is a progressive neurodegenerative movement disorder, affecting mainly the el...
The most commonly used treatment for Parkinson’s disease (PD) is levodopa, prescribed in conjunction...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
Levodopa (LD) is the most effective drug in the treatment of Parkinson's disease (PD). However, alth...
Pharmacotherapy for Parkinson’s disease (PD) is based on levodopa, the most effective dopaminergic d...
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina,...
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic eff...
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in do...
Thomas Müller Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, 13088, Ge...
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms inc...
Three decades after its introduction, levodopa remains the gold standard for the treatment of Parkin...
Introduction: The clinical diagnosis of Parkinson’s disease (PD) is based on the identification of b...
Parkinson’s disease (PD) is a neurodegenerative disease affecting approximately 25000 people in Swed...
Motor complications in response to levodopa therapy are major problems in the treatment of Parkinson...
Parkinson\u27s disease is a progressive neurodegenerative movement disorder, affecting mainly the el...
The most commonly used treatment for Parkinson’s disease (PD) is levodopa, prescribed in conjunction...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
Levodopa (LD) is the most effective drug in the treatment of Parkinson's disease (PD). However, alth...
Pharmacotherapy for Parkinson’s disease (PD) is based on levodopa, the most effective dopaminergic d...
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina,...
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic eff...
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in do...
DOI
Add to ORKG